Loading…
Employees: 8,538
Size Modern Dental (3600.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $871M, the 627th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$7.32 on 6 Nov 2026.
Performance Over six months the shares gained 19.4%, against -12.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 12.5% over the last twelve months (peer median +8.1%); the operating margin is 22.2% (peer median 10.2%).
Valuation It trades at 8.8× forward earnings against a peer median of 20.0× (2nd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.7 points above its cost of capital (8.2% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.93B | HK$3.74B | HK$3.36B | HK$3.17B | HK$2.83B |
| Revenue growth | — | +11% | +6% | +12% | — |
| Gross profit | HK$2.26B | HK$2.08B | HK$1.80B | HK$1.70B | HK$1.38B |
| EBITDA | HK$1.02B | HK$899M | HK$720M | HK$684M | HK$454M |
| Net income | HK$686M | HK$597M | HK$408M | HK$404M | HK$220M |
| Free cash flow | n/a | HK$666M | HK$326M | HK$377M | HK$53.4M |
| Capital expenditure | n/a | HK$72.0M | HK$154M | HK$160M | HK$185M |
| Total debt | n/a | HK$654M | HK$924M | HK$852M | HK$788M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3600.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -3.3% | 9th lowest of 21 |
| 6-month return | +19.4% | -12.4% | 5th highest of 21 |
| Distance from 52-week high | -14.3% | -32.0% | 6th highest of 21 |
| Revenue growth (TTM) | +12.5% | +8.1% | 9th highest of 21 |
| Operating margin | 22.2% | 10.2% | 3rd highest of 21 |
| Forward P/E | 8.8× | 20.0× | 2nd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -7.0% | 6.9% | 3rd least demanding of 16 |
| Growth delivered (Del g) | +11.3% | +12.1% | 7th lowest of 16 |
| Hurdle (Req g minus delivered) | -18.3 pp | -3.4 pp | 3rd least demanding of 16 |
| ROIC minus cost of capital | +13.7 pp | +1.4 pp | 2nd highest of 21 |
| EV / EBITDA | 6.5× | 11.2× | 3rd cheapest of 12 |
| Net debt / EBITDA | -0.2× | -0.2× | 7th least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |